Q2 2025 Earnings Call Transcript August 7, 2025 Intellia Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

GAAP revenue of $14.2 million for Q2 2025 beat analyst estimates and Revenue more than doubled year over year in the second quarter, beating analyst estimates. Net loss per share (GAAP) narrowed to ...

Enrollment in the global Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) in ATTR with cardiomyopathy (ATTR-CM) continues to trac ...

In July 2025, Novartis Pharmaceuticals announced a phase III study to assess efficacy and safety of crizanlizumab (5 mg/kg) ...

Among other items, Intellia announced that it plans to focus its resources on developing drug candidates NTLA-2002 and nex-z and will discontinue development of NTLA-3001, which will result in the ...

Among other items, Intellia announced that it plans to focus its resources on developing drug candidates NTLA-2002 and nex-z and will discontinue development of NTLA-3001, which will result in the ...

Among other items, Intellia announced that it plans to focus its resources on developing drug candidates NTLA-2002 and nex-z and will discontinue development of NTLA-3001, which will result in the ...